# US 2004/0018236 A1 · Nanoparticles for oral administration of pharmaceutical agents of low solubility

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0018236 A1
- Document ID: US20040018236A1
- Status: Published application
- Kind: A1
- Application number: 10/623,888
- Filed: 2003-07-17
- Published: 2004-01-29
- Earliest claimed: 1995-05-08
- Inventors: Robert Gurny; Eric Olivier Allemann; Jean-Christophe Leroux
- Web page: https://patentgrep.com/patent/US20040018236A1

## CPC

- A61K 9/5138: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/5192: {Processes}
- A61K 31/537: spiro-condensed or forming part of bridged ring systems
- A61K 47/02: Inorganic compounds
- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- A61P 31/18: for HIV
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to pharmaceutical compositions for the oral administration of pharmaceutical agents having low water solubility. Those agents are solubilized with a polymer suitable for the formation of nanoparticles, especially from the EUDRAGIT L and S series which release the active agent in specific target regions of the gastrointestinal tract.

## Claims

### Claim 1

A pharmaceutical composition for the oral administration of an active agent having low water solubility, wherein
a) the active agent is dispersed in an aqueous formulation base; and
b) the solubilizing agent is suitable for the formation of an aqueous dispersion of nanoparticles;
which is characterized in that the solubilizing agent is a pharmaceutically acceptable polymer which is resistant to gastric juices and soluble in intestinal juices.

### Claim 2 (depends on 1)

A pharmaceutical composition according to claim 1, wherein the polymer, which is resistant to gastric juices and soluble in intestinal juices is a copolymer from monomers selected from the group consisting of methacrylic acid, methacrylic acid esters, acrylic acid and acrylic acid esters.

### Claim 3 (depends on 1)

A pharmaceutical composition according to claim 1, wherein the polymer, which is resistant to gastric juices and soluble in intestinal juices is a pharmaceutically acceptable cellulose derivative selected from the group consisting of hydroxypropyl methyl cellulose acetate succinate (HPMCAS), hydroxypropylmethylcellulose-phthalate (HPMCP), celluloseacetate-phthalate (CAP), and celluloseacetatetrimellitate (CAT).

### Claim 4 (depends on 2)

A pharmaceutical composition according to claim 2, wherein the polymer is a 1:1-up to 1:2-copolymer from monomers selected from the group consisting of methacrylic acid and methacrylic acid lower alkyl esters.

### Claim 5 (depends on 4)

A pharmaceutical composition according to claim 4, wherein the copolymer is a 1:1-up to 1:2-copolymer of methacrylic acid and methacrylic acid methyl ester.

### Claim 6 (depends on 2)

A pharmaceutical composition according to claim 2, wherein the copolymer is a 1:1-copolymer of methacrylic acid and acrylic acid ethyl ester.

### Claim 7 (depends on 1)

A pharmaceutical composition according to claim 1, wherein the solubilizing agent is suitable for the formation of nanospheres.

### Claim 8 (depends on 1)

A pharmaceutical composition according to claim 1, wherein the formulation base contains water soluble additives suitable for incorporation in a dosage form intended for oral administration.

### Claim 9 (depends on 1)

A process for the preparation of the pharmaceutical composition according to claim 1, which is characterized in that an aqueous dispersion of nanoparticles containing a) the active agent to be solubilized and b) the solubilizing agent, which is suitable for the formation of an aqueous dispersion of nanoparticles, is formed; and the dispersion is processed further under the optional addition of pharmaceutically acceptable additives c), which are suitable for the incorporation in a dosage form for the oral administration.

### Claim 10 (depends on 9)

A process according to claim 9, characterized in that the aqueous dispersion of nanoparticles is processed further to a lyophilisate.

### Claim 11 (depends on 9)

A process according to claim 9, characterized in that the aqueous dispersion of nanoparticles is filled into starch, hard gelatin or soft gelatin capsules.
